Today's Daily Dose brings you news about Akebia's phase II trial of kidney disease drug; Ascendis' progress in hypoparathyroidism trial; Avinger's receipt of CE Mark; disappointing results of Mateon's FOCUS study and Psychemedics' launch of hair test.
from RTT - Biotech http://ift.tt/2fpKBXT
via IFTTT
No comments:
Post a Comment